Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5997657 | 0.68 | ACHE (0.41) | — | |
| SCHEMBL5685748 | 0.61 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Hydrochloric Acid SCHEMBL5995778 | 0.60 | CHRNB2 (0.97) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL4404195 | 0.58 | CHRNB2 (0.46) | CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL1998740 | 0.57 | DRD2 (0.41) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL4406720 | 0.56 | CHRNB2 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL746571 | 0.56 | — | — | |
| SCHEMBL697445 | 0.56 | — | — | |
| SCHEMBL8884797 | 0.55 | KDM1A (0.66) | — | |
| Lithium SCHEMBL8775004 | 0.55 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122534-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2006-10-17 | — | — | US | disclosed |
| US-6706702-B2 | FOR THERAPY OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | PFIZER INC. | 2004-03-16 | — | — | US | disclosed |
| EP-1076650-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030130261-A1 | Aryl fused azapolycyclic compounds | PFIZER INC | 2003-07-10 | — | — | US | disclosed |
| US-20030008890-A1 | Aryl fused azapolycyclic compounds | COE JOTHAM WADSWORTH (US) | 2003-01-09 | — | — | US | disclosed |
| US-6462035-B1 | BINDING TO NEURONAL NICOTINIC ACETYLCHOLINE SPECIFIC RECEPTOR; MODULATING CHOLINERGIC FUNCTION; REDUCING NICOTINE ADDICTION; INFLAMMATORY AND IRRITABLE BOWEL SYNDROME, SPASTIC DYSTONIA, CHRONIC AND ACUTE PAIN, EATING DISORDERS | PFIZER INC. | 2002-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130261-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN3A | CHRNB2 297/4885CHRNB4 524/4885CHRNA3 161/4885 |
| US-20030008890-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, NR3C1 | CHRNB2 309/4885CHRNB4 443/4885CHRNA3 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.